Drug Trial Radar · NCT00348504
Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support: a Multicentre, Parallel-Group, Randomised, Double-Blind, Double-Dummy Study of Levosimendan Versus Dobutamine in Patients With Acute Heart Failure.
Last checked: Nov 19, 2026Latest source record: Nov 20, 2007 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,300
Actual
Start
Mar 2003
Primary completion
Not stated
Study completion Jun 2005
Sponsor
- Lead sponsor
- AbbottIndustry
- Sponsor type
- Industry
- Collaborators
- Orion Corporation, Orion Pharma
- First posted
- Jul 4, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to compare the efficacy of levosimendan and dobutamine on all-cause mortality in the 180 days following randomization.
Conditions
- Acute Heart Failure
Interventions
levosimendanDrug
dobutamineDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- All-cause mortality in the 180 days following randomization.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Global Medical Information - Abbott
Abbott Park, Illinois
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.